文献速递神经核医学肿瘤 PET/CT

促胰液素通过棕色脂肪组织-大脑轴调节食欲

Secretin modulates appetite via brown adipose tissue-brain axis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-02-11

该安慰剂对照、单盲神经影像研究在人体中采用[18F]-FDG PET(n=15)、功能磁共振(fMRI;n=14)及PET-fMRI融合分析(n=10),发现促胰液素经棕色脂肪组织-大脑轴调节脑葡萄糖消耗,改善抑制控制并下调对诱人食物图像的脑反应,提示其可能通过调节神经代谢耦合诱导饱腹感。

要点

  • 促胰液素条件下棕色脂肪组织与尾状核葡萄糖摄取呈负相关(r=-0.54,p=0.037),安慰剂条件下无此相关。
  • 促胰液素改善抑制控制并下调大脑对诱人食物图像的反应。
  • PET-fMRI融合分析显示促胰液素诱导的神经代谢耦合模式促进饱腹感。

核心结论

  • 促胰液素可能通过调节棕色脂肪组织-大脑代谢交互及随后的神经代谢耦合来诱导饱腹感。
  • 该研究增进了对促胰液素在动机性进食行为中信号作用的理解,并提示促胰液素在治疗进食障碍和肥胖方面的潜在作用。

研究设计与样本

  • 安慰剂对照、单盲神经影像研究,首先采用[18F]-FDG PET测量(n=15),随后采用功能磁共振成像(fMRI;n=14),最后进行PET-fMRI融合分析(n=10)。
  • 试验注册:EudraCT编号2016-002373-35,2016年6月2日注册;Clinical Trials编号NCT03290846,2017年9月25日注册。

主要发现

  • 在促胰液素条件下,棕色脂肪组织与尾状核葡萄糖摄取水平呈负相关(r=-0.54,p=0.037),安慰剂条件下无此相关性。
  • 促胰液素改善抑制控制并下调大脑对诱人食物图像的反应。
  • PET-fMRI融合分析显示尾状核葡萄糖摄取与奖赏及抑制相关神经活动之间存在模式化对应,促胰液素诱导的神经代谢耦合模式促进饱腹感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Secretin activates brown adipose tissue (BAT) and induces satiation in both mice and humans. However, the exact brain mechanism of this satiety inducing, secretin-mediated gut-BAT-brain axis is largely unknown. METHODS AND RESULTS: In this placebo-controlled, single-blinded neuroimaging study, firstly using [18F]-fluorodeoxyglucose (FDG) PET measures (n = 15), we established that secretin modulated brain glucose consumption through the BAT-brain axis. Predominantly, we found that BAT and caudate glucose uptake levels were negatively correlated (r = -0.54, p = 0.037) during secretin but not placebo condition. Then, using functional magnetic resonance imaging (fMRI; n = 14), we found that secretin improved inhibitory control and downregulated the brain response to appetizing food images. Finally, in a PET-fMRI fusion analysis (n = 10), we disclosed the patterned correspondence between caudate glucose uptake and neuroactivity to reward and inhibition, showing that the secretin-induced neurometabolic coupling patterns promoted satiation. CONCLUSION: These findings suggest that secretin may modulate the BAT-brain metabolic crosstalk and subsequently the neurometabolic coupling to induce satiation. The study advances our understanding of the secretin signaling in motivated eating behavior and highlights the potential role of secretin in treating eating disorders and obesity. TRIAL REGISTRATION: EudraCT no. 2016-002373-35, registered 2 June 2016; Clinical Trials no. NCT03290846, registered 25 September 2017.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sun L, Laurila S, Lahesmaa M, et al. Secretin modulates appetite via brown adipose tissue-brain axis. Eur J Nucl Med Mol Imaging. 2023. PMID: 36764966. doi:10.1007/s00259-023-06124-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。